Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Rush University Medical Center |
---|---|
Information provided by: | Rush University Medical Center |
ClinicalTrials.gov Identifier: | NCT00613600 |
Overweight and obesity are serious and growing problems within the United States. The usual approaches to weight loss-dieting, exercise, and behavioral interventions-rarely result in long-term weight loss. Therefore, we will evaluate the safety and efficacy of glucomannan, a fiber supplement that has promising weight loss effects.
Condition | Intervention | Phase |
---|---|---|
Overweight Obesity |
Dietary Supplement: Glucomannan Dietary Supplement: Inert microcrystalline cellulose |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Safety and Efficacy of Glucomannan for Weight Loss |
Estimated Enrollment: | 50 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | August 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Two 665 mg capsules of glucomannan three times a day for eight weeks
|
Dietary Supplement: Glucomannan
Two 665 mg capsules of glucomannan three times a day for 8 weeks
|
2: Placebo Comparator
Two capsules of inert microcrystalline cellulose three times a day for eight weeks
|
Dietary Supplement: Inert microcrystalline cellulose
Two capsules of inert microcrystalline cellulose three times a day for eight weeks
|
The primary objective of this exploratory project is to evaluate the safety and efficacy of a highly viscous, water-soluble fiber supplement, glucomannan, for achieving weight loss in overweight and moderately obese individuals. Overweight and obesity are major public health problems in the U.S. that account for substantial morbidity, mortality, and healthcare costs. Conventional approaches to weight loss are largely ineffective, particularly for long-term weight loss and maintenance. Thus, there is a critical need for safe and effective adjunctive treatments. A few, limited studies suggest that glucomannan supplementation is associated with weight loss, is well-tolerated, and has a favorable safety profile.
In this preliminary study, the target population will be overweight and moderately obese individuals, a population that accounts for nearly 50% of all U.S. adults. The specific aims of the project are to: 1) describe the safety of glucomannan for achieving weight loss in overweight and moderately obese individuals, and 2) describe the efficacy of glucomannan for achieving weight loss in overweight and moderately obese individuals. Participants will take glucomannan supplements daily for eight weeks in a double-blind, placebo-controlled, randomized clinical trial. Safety and efficacy outcome measures include: gastrointestinal symptoms/tolerance, hepatic panel, serum creatinine, weight, body composition, diet intake, hunger/fullness, lipid profile, blood glucose, and C-reactive protein. Examination of the safety and efficacy of glucomannan for achieving weight loss will extend our understanding of additional treatments that may be effective in combating a significant public health problem.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Illinois | |
Rush University Medical Center | |
Chicago, Illinois, United States, 60612 |
Principal Investigator: | Joyce K Keithley, DNSc, RN | Rush University Medical Center |
Responsible Party: | Rush University Medical Center ( Joyce K. Keithley, Professor ) |
Study ID Numbers: | RTF-GM |
Study First Received: | January 31, 2008 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00613600 |
Health Authority: | United States: Institutional Review Board |
Safety Efficacy Glucomannan Dietary fiber Weight loss |
Body Weight Signs and Symptoms Obesity (1-6)-alpha-glucomannan Weight Loss |
Body Weight Changes Nutrition Disorders Overnutrition Overweight |
Therapeutic Uses Gastrointestinal Agents Cathartics Pharmacologic Actions |